REG - BSF Enterprise PLC - 3DBT Lab Grown Leather Commercialization

BSF EnterpriseAnnouncement

13/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250313:nRSM4353Aa&default-theme=true

RNS Number : 4353A  BSF Enterprise PLC  13 March 2025

 

 

 

 

London, 12 March 2025

 

BSF Enterprise PLC

 

3DBT Accelerates

Lab-Grown Leather Commercialization

 

 

BSF Enterprise PLC (BSF), a leading innovator in tissue-engineered materials,
is pleased to announce that its subsidiary, 3D Bio-Tissues Ltd (3DBT), has
stepped up it's activities to commercialise the Lab-grown Leather business as
part of the £50,000 Northern Accelerator Growth Support Grant.

 

BSF has previously formed a wholly owned subsidiary - Lab-grown Leather Ltd
(LGL) and together with 3DBT they are taking steps aimed to transition the
lab-grown leather technology from lab-scale to pilot plant and accelerate
fundraising for its future commercialization.

 

LGL has entered collaborations with third parties to undertake market research
to validate high-growth opportunities, evidence-defined revenue streams and
align commercial efforts with key sectors such as fashion, jewellery, and
automotive. It will also develop a comprehensive technology roadmap for a
scalable production process and a clear plan for setting up a pilot plant.

 

This also involves developing a full business case for investment  into LGL
as a stand-alone entity in the lab-grown leather emerging industry. This
investment will be non-dilutive to investors in BSF and will help position us
to highlight the value of our advanced technology to new investors directly
into LGL.

 

Further information will be released as we conclude the first stage of this
development.

 

 

Dr. Che Connon, CEO and Founder of 3DBT, commented, "These collaborations have
been developed over many months of discussions and will be critical in our
launch of Lab-Grown Leather Ltd. It enables us to further accelerate the
commercialization of our technology and scale up manufacturing."

 

3DBT and LGL remain committed to revolutionizing the leather industry through
sustainable innovation and will provide further updates as the roadmap and
pilot plant development progress.

 

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Geoff Baker - Executive Director

Che Connon - CEO & Director

 

Shard Capital (Broker)

Damon Heath

Isabella Pierre

0207 186 9000

0207 186 9927

 

About BSF Enterprise PLC BSF Enterprise PLC (BSF) develops and commercialises
cutting-edge tissue-engineered solutions, including lab-grown leather,
cultivated meat, and corneal repair technologies. By leveraging its
proprietary scaffold-free platform, BSF aims to deliver sustainable
alternatives to traditional materials and meet global demand for
environmentally responsible innovations.

 

About 3D Bio-Tissues 3D Bio-Tissues (3DBT) specialises in the creation of
lab-grown tissues using advanced bioengineering techniques. Its scaffold-free
lab-grown leather technology replicates the composition, texture, and
performance of traditional leather without environmental and ethical
drawbacks. For more information, visit www.3dbiotissues.com
(https://www.3dbiotissues.com/) .

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPURCWUPAGQP